AtaiBeckley (ATAI) Accumulated Depreciation (2023 - 2025)
AtaiBeckley (ATAI) recorded quarterly Accumulated Depreciation of $405000.0 in Q4 2025, up 1.76% quarter-over-quarter from $398000.0 in Q4 2024, and up 1.76% on a YoY basis from $398000.0 in Q4 2024.
AtaiBeckley (ATAI) Accumulated Depreciation (2023 - 2025) Analysis & Trends
AtaiBeckley's Accumulated Depreciation history runs 2 years deep, the most recent figure standing at $405000.0 for Q4 2025.
- In Q4 2025, Accumulated Depreciation rose 1.76% year-over-year to $405000.0; the TTM figure through Dec 2025 stood at $405000.0 (up 1.76% YoY), while the FY2025 annual figure was $405000.0, up 1.76% from the prior year.
- Accumulated Depreciation was $405000.0 for Q4 2025 at AtaiBeckley, up from $398000.0 in the prior quarter.
- In the past five years, Accumulated Depreciation ranged from a high of $398000.0 in Q4 2024 to a low of $153000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | AtaiBeckley | 1.45 Bn | 1.45 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 405,000.00 |
| Dec 31, 2024 | 398,000.00 |
| Dec 31, 2024 | 398,000.00 |
| Dec 31, 2023 | 153,000.00 |